Vertex Pharmaceuticals Incorporated (Public, NASDAQ:VRTX) Vertex presents mixed results in hepatitis C drug 30th October 2006 By Victoria Harrison Vertex has presented mixed results from its phase Ib trial of its hepatitis C drug, saying that some patients still had the virus when combined with ribavirin. The study examined Vertex's investigational hepatitis C virus protease inhibitor, telaprevir in combination with pegylated interferon (peg-IFN) with or without ribavirin.
The hepatitis C virus was suppressed in patients when pegylated interferon was added to telaprevir in the phase Ib clinical study More here: http://www.pharmaceutical-business-review.com/article_news.asp?guid=47B35064-373A-4E2F-A667-8B3538B4911F http://tech.groups.yahoo.com/group/biotech-news/ http://www.arizonabiotech.com/ http://www.azhttp.com/ http://www.arizonabiotech.com/ http://groups.yahoo.com/group/biotech-news/ http://www.arizonaentrepreneurs.com/ http://www.azhttp.com/ Yahoo! Groups Links <*> To visit your group on the web, go to: http://groups.yahoo.com/group/biotech-news/ <*> Your email settings: Individual Email | Traditional <*> To change settings online go to: http://groups.yahoo.com/group/biotech-news/join (Yahoo! ID required) <*> To change settings via email: mailto:[EMAIL PROTECTED] mailto:[EMAIL PROTECTED] <*> To unsubscribe from this group, send an email to: [EMAIL PROTECTED] <*> Your use of Yahoo! Groups is subject to: http://docs.yahoo.com/info/terms/
